Clinical Trials
National/International Multicenter Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Efficacy And Safety Of Rifaximin Soluble Solid Dispersion (Ssd) Tablets For The Delay Of Encephalopathy Decompensation In Cirrhosis (Red-C)
Duration: 2023-ongoing
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Duration: 2024-ongoing
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects without Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Duration: 2024-ongoing
A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD4831 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis
Duration: 2023-2025 Completed
NASH PASS: A Population-based Epidemiological NAFLD/NASH Registry and Research Project
Duration: 2023-2024 completed
Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of STUDY DRUG in Subjects with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
Completed 2023
A Communication -Based Study Focused On Assessing And Improving Hepatitis C Screening Rates, As Well As Treatment Rates In Arizona As A Step Towards Disease Eradication
Duration: 2021 - 2026
NASH: Regeneron Protocol Title/Number: N/A Exploratory Biomarker study in Adults (above 18 Years) with Nonalcoholic Steatohepatitis (NASH FNA/CNB CES) / R0000-NASH-CES-1945
Duration: 2021 - 2022 completed
REEMPT CRC: Prevention of Colorectal Cancer Through Multiomics Blood Testing
Duration: Aug 2021- Dec 2021 Completed
Phase 2a Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MET642 in Patients with Nonalcoholic Steatohepatitis (NASH)
Duration: 2021 - 2022 Completed
Phase 2a Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MET642 in Patients with Nonalcoholic Steatohepatitis (NASH)
Duration: Mar 2021- Dec 2021 completed
NASH PASS: A population based epidemiological NAFLD/NASH registry and research project
Duration: Sep 2021- Jul 2021
Completed 2022
A study to evaluate narrow gauge core needle biopsy samples for measuring gene expression in the liver in patients with nonalcoholic steatohepatitis
Duration: December 2020- May 2021 Completed
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH)
Duration: Feb 2020- March 2021 Completed